サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1620332

術後疼痛治療薬の世界市場規模：薬剤クラス別、投与経路別、流通チャネル別、地域別、範囲および予測

Global Postoperative Pain Therapeutics Market Size By Drug Class, By Route Of Administration, By Distribution Channel, By Geographic Scope And Forecast

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
術後疼痛治療薬の世界市場規模：薬剤クラス別、投与経路別、流通チャネル別、地域別、範囲および予測
出版日: 2024年10月20日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

術後疼痛治療薬の市場規模と予測

術後疼痛治療薬の市場規模は、2023年に121億6,000万米ドルと評価され、2024年～2031年の間に3.89％のCAGRで成長する見込みで、2031年には164億9,000万米ドルに達すると予測されています。術後疼痛治療薬は、外科手術後に患者が経験する疼痛を管理するための医療介入や治療を指します。術後疼痛治療薬は、苦痛を軽減し、治癒を促進し、手術後の全体的な回復を改善することを目的としています。このような治療法には、各患者の特定のニーズや実施された手術の種類に適応した、さまざまな薬理学的および非薬理学的手法が含まれます。

オピオイド、非ステロイド性抗炎症薬（NSAIDs）、局所麻酔薬は、薬理療法でよく用いられる鎮痛薬です。非薬物療法としては、理学療法、鍼治療、リラクゼーション体操などがあります。

さらに、術後疼痛治療薬は、小規模な外来手術からより侵襲的な手術まで、幅広い医療専門分野や外科手術で使用されています。

術後疼痛治療薬市場力学

術後疼痛治療薬市場を形成している主な市場力学

主な市場促進要因

手術手技の増加：

高齢化、慢性疾患、手術手技の技術開発などによる世界の外科手術の増加が、術後の疼痛を効果的に管理する術後疼痛治療薬の必要性を高めています。

疼痛管理に対する認識と期待：

患者や医療従事者の間で、適切な疼痛管理の必要性に対する認識が高まっています。その結果、快適な回復時間に対する患者の期待が高まり、高度な術後疼痛治療薬の需要が高まっています。

医薬品の革新と承認：

非オピオイド代替薬を含む、新しく効果的な疼痛治療薬の開発と承認が重要な推進力となっています。また、副作用を最小限に抑えながらより長時間の疼痛緩和を実現するドラッグデリバリーシステムの革新も、市場を後押ししています。

政府とヘルスケア政策：

医療施設における効果的な疼痛管理基準を奨励する政府の規則やガイドラインは、高度な治療薬の使用を刺激します。疼痛管理薬や治療法を優遇する償還規則が術後疼痛治療薬市場を後押ししています。

主な課題

オピオイド危機と規制：

オピオイド危機の結果、オピオイド処方に関する法律が厳格化され、市場のプレーヤーにとってハードルとなっています。オピオイドを使用しない疼痛治療薬への需要は高まっているが、オピオイドと同等の効果を持つ代替薬の開発は複雑です。

疼痛管理薬の副作用：

多くの術後疼痛管理薬には吐き気、嘔吐、便秘などの副作用があり、中毒を引き起こす可能性があるため、使用が控えられています。副作用の少ない薬の開発も市場開拓の重要な課題です。

臨床と規制上のハードル：

革新的な疼痛管理製品を市場に投入するには、大規模な臨床試験と規制当局の認可が必要です。これらのプロセスには時間とコストがかかるため、術後疼痛治療薬市場への新規薬剤や技術の参入には大きな障壁となっています。

主要動向：

非オピオイド薬への需要の高まり：

オピオイド中毒への懸念から、非オピオイド療法への大きなシフトが進んでいます。そのため、製薬企業は、オピオイドの危険性を伴わずに術後疼痛を効果的に治療する非中毒性の疼痛管理治療を開発しています。

マルチモーダル疼痛管理の台頭：

疼痛を治療するために複数のアプローチや薬剤を組み合わせる「マルチモーダル疼痛管理」は、市場でますます人気が高まっています。この方法は、疼痛緩和を改善し副作用を最小限に抑えることで、患者の回復を早め、入院期間を短縮しようとするものです。

外来手術センターの成長：

効果的な術後疼痛治療薬は、外来手術センター（ASC）の成長により需要が高まっています。ASCは病院での手術に代わる費用対効果の高い選択肢を提供し、患者の回復時間の短縮と疼痛管理プロトコルの強化に注力しています。

ドラッグデリバリーシステムの進歩：

術後疼痛管理の有効性と利便性を向上させるため、経皮吸収パッチや埋め込み型デバイスなど、新しい薬物送達システムの開発が重視されるようになってきています。これらの技術により、薬物の放出が調節されるため、頻繁に投与することなく常に痛みを和らげることができます。

術後疼痛治療薬市場の地域分析

術後疼痛治療薬市場の詳細な地域分析

北米：

Verified Market Researchによると、北米は予測期間中、術後疼痛治療薬市場を独占すると予測されています。北米は、洗練されたヘルスケアインフラと患者の医療へのアクセスにより、外科手術の数が非常に多く、回復をうまく管理するための術後疼痛治療薬の需要を促進しています。

この地域では現在、オピオイド危機が発生しており、オピオイドを使用しない疼痛管理の選択肢が非常に注目されています。規制機関やヘルスケア関係者は、中毒を助長することなく術後疼痛を管理する、より安全で効果的な方法に注力しています。

北米には大手製薬会社や研究機関が存在し、非オピオイド薬や新規ドラッグデリバリー法などの革新的な疼痛管理薬の開発を推進していることが、市場の成長を後押ししています。

さらに、北米では外来手術センター（ASC）が拡大し、費用対効果が高く効率的な外科治療が行われているため、タイムリーな回復と患者の満足度を確保するための術後疼痛管理オプションの強化が求められています。

アジア太平洋：

アジア太平洋地域は、市場推計・予測期間中に最も高いCAGRで成長すると推定されます。アジア太平洋地域では、適切な術後疼痛治療を必要とする外科手術の増加に対応するため、病院や手術センターなどのヘルスケアインフラが著しく成長しています。

日本、中国、インドなどの国々では、慢性疾患にかかりやすい高齢者人口が増加しており、外科手術が必要となるため、術後疼痛治療薬の需要が高まっています。

ヘルスケア専門家や患者は、適切な疼痛管理の必要性をより強く認識するようになっており、この地域の術後疼痛治療薬市場における高度な治療への需要を押し上げています。

さらに、アジア太平洋地域の経済開発により、ヘルスケア支出や医学研究への投資が増加し、先進的な術後疼痛管理オプションの開発が促進されています。

欧州：

欧州では疼痛管理薬、特にオピオイドの使用に関する規制が厳しく、革新的で安全な術後疼痛治療薬への需要が高まっています。

欧州では、毎年相当数の選択的・非選択的手術が行われるため、患者の回復を高め、入院期間を短縮するための効率的な術後疼痛管理ソリューションに対する需要が高いです。

手術後の痛みを包括的に緩和するため、欧州のヘルスケアシステムでは、医薬品と非薬物療法を組み合わせたマルチモーダルな疼痛治療戦略の導入が進んでいます。

さらに、革新的なドラッグデリバリー方法や非オピオイド薬の開発など、欧州のヘルスケア革新への取り組みは、効果的で患者に優しい代替手段を提供することで、術後疼痛治療市場の成長を後押ししています。

目次

第1章 世界の術後疼痛治療薬市場：イントロダクション

  • 市場概要
  • 調査範囲
  • 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • 検証
  • プライマリーインタビュー
  • データソース一覧

第4章 世界の術後疼痛治療薬市場展望

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析

第5章 術後疼痛治療薬の世界市場：薬剤クラス別

  • 概要
  • オピオイド
  • 非ステロイド性抗炎症薬（NSAIDs）
  • 局所麻酔薬
  • 三環系抗うつ薬
  • 抗てんかん薬
  • その他

第6章 術後疼痛治療薬の世界市場：投与経路別

  • 概要
  • 経口剤
  • 筋肉内
  • 静脈内投与
  • その他

第7章 術後疼痛治療薬の世界市場：流通チャネル別

  • 概要
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第8章 術後疼痛治療薬の世界市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他アジア太平洋地域
  • 世界のその他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第9章 世界の術後疼痛治療薬市場：競合情勢

  • 概要
  • 各社の市場ランキング
  • 主な開発戦略

第10章 企業プロファイル

  • AbbVie
  • Johnson & Johnson
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Merck & Co. Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca plc
  • Eli Lilly and Company
  • GlaxoSmithKline plc

第11章 主な発展

  • 製品上市／開発
  • 合併と買収
  • 事業拡大
  • パートナーシップと提携

第12章 付録

  • 関連調査
目次
Product Code: 11282

Postoperative Pain Therapeutics Market Size And Forecast

Postoperative Pain Therapeutics Market size was valued at USD 12.16 Billion in 2023 and is projected to reach USD 16.49 Billion by 2031 , growing at a CAGR of 3.89% from 2024 to 2031. Postoperative pain therapeutics refers to medical interventions and treatments used to manage pain experienced by patients following surgical procedures. Postoperative pain therapeutics aim to reduce suffering, increase healing, and improve overall recovery after surgery. These therapeutics include a variety of pharmacological and non-pharmacological techniques that are adapted to each patient's specific needs and the type of operation performed.

Opioids, nonsteroidal anti-inflammatory medicines (NSAIDs), and local anesthetics are popular analgesics used in pharmacological therapies. Non-pharmacological therapies include physical therapy, acupuncture, and relaxation exercises.

Furthermore, postoperative pain therapeutics are used in a wide range of medical specializations and surgical procedures, from small outpatient procedures to more invasive operations.

Postoperative Pain Therapeutics Market Dynamics

The key market dynamics that are shaping the Postoperative Pain Therapeutics Market include:

Key Market Drivers

Rising Surgical Procedures:

The global increase in surgical procedures due to aging populations, chronic diseases, and technical developments in surgery techniques is driving the need for postoperative pain therapeutics to effectively manage pain after surgery.

Awareness and Expectation for Pain Management:

Patients and healthcare providers are becoming increasingly aware of the necessity of proper pain management. As a result, advanced postoperative pain therapeutics are in high demand due to rising patient expectations for comfortable recovery times.

Pharmaceutical Innovations and Approvals:

The development and approval of new and effective pain treatment medications, including non-opioid alternatives, are important drivers. Drug delivery system innovations that provide longer pain relief while minimizing negative effects also helping drive market.

Government and Healthcare Policies:

Government rules and guidelines encouraging effective pain management standards in healthcare facilities stimulate the use of sophisticated therapeutics. Reimbursement rules that favor pain management medications and therapies are propelling the Postoperative Pain Therapeutics Market.

Key Challenges:

Opioid Crisis and Regulation:

The opioid crisis has resulted in stringent opioid prescription laws, which pose hurdles for players in the market. The demand for non-opioid pain treatment solutions is growing, but creating alternatives that are as effective as opioids is complicated.

Side Effects of Pain Management Drugs:

Many postoperative pain management medicines have side effects, such as nausea, vomiting, constipation, and the potential for addiction is discouraging their usage. Developing medications with minimal side effects is also an important challenge in the market.

Clinical and Regulatory Hurdles:

Bringing innovative pain management products to market needs extensive clinical testing and regulatory authorization. These processes are time-consuming and costly, creating significant barriers to the entry of novel medications and technologies into the Postoperative Pain Therapeutics Market.

Key Trends:

Increasing Demand for Non-Opioid Medications:

Concerns about opioid addiction are driving a huge shift towards non-opioid therapies. Thus, pharmaceuticals are developing non-addictive pain management treatments that effectively cure postoperative pain without the hazards of opioids.

Rise of Multimodal Pain Management:

Multimodal pain management, which combines several approaches and drugs to treat pain, is becoming increasingly popular in the market. This method attempts to improve pain relief and minimize adverse effects, resulting in faster patient recovery and shorter hospital stays.

Growth in Ambulatory Surgical Centers:

Effective postoperative pain therapeutics are in high demand due to the growth of ambulatory surgical centers (ASCs). ASCs provide a cost-effective alternative to hospital-based surgeries, focusing on reducing patient recovery time and enhancing pain management protocols.

Advancements in Drug Delivery Systems:

There is a rising emphasis on creating novel medication delivery systems, such as transdermal patches and implanted devices, to improve the efficacy and convenience of post-operative pain management. These technologies provide regulated medication release, resulting in constant pain relief without frequent dosage.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Postoperative Pain Therapeutics Market Regional Analysis

Here is a more detailed regional analysis of the Postoperative Pain Therapeutics Market:

North America:

According to Verified Market Research, North America is estimated to dominate the Postoperative Pain Therapeutics Market during the forecast period. North America has an important number of surgical procedures due to sophisticated healthcare infrastructure and patient access to medical care, driving the demand for postoperative pain therapeutics to successfully manage recovery.

With the present opioid crisis in this region, there is a tremendous push for non-opioid pain management alternatives. Regulatory agencies and healthcare practitioners are concentrating on safer, more effective ways to manage postoperative pain without contributing to addiction.

The presence of major pharmaceutical companies and research institutions in North America promotes the development of innovative pain management medicines, such as non-opioid medications and novel drug delivery methods is propelling the growth of the market.

Furthermore, the expansion of ambulatory surgical centers (ASCs) in North America, which provide cost-effective and efficient surgical treatment is demanding enhanced postoperative pain management options to ensure timely recovery and patient satisfaction.

Asia Pacific:

Asia Pacific is estimated to grow at the highest CAGR within the market during the forecast period. Asia Pacific is experiencing tremendous growth in healthcare infrastructure, including hospitals and surgical centers, to accommodate an increasing number of surgical procedures that necessitate adequate postoperative pain treatment.

The growing older population in countries such as Japan, China, and India, which are more prone to chronic illnesses necessitate surgical procedures, thereby boosting demand for postoperative pain therapeutics.

Healthcare professionals and patients are becoming more conscious of the necessity of appropriate pain management, driving up demand for sophisticated treatments in the Postoperative Pain Therapeutics Market in this region.

Furthermore, economic development in the Asia-Pacific region has resulted in increasing healthcare spending and medical research investments, facilitating access to the development of advanced postoperative pain management options.

Europe:

Europe's stringent regulatory framework for pain management medications, particularly opioid use, fuels demand for innovative and safer postoperative pain therapies.

With a significant number of elective and non-elective surgeries conducted each year, Europe has a high demand for efficient postoperative pain management solutions to improve patient recovery and shorten hospital stays.

To provide comprehensive pain relief following surgery, European healthcare systems are increasingly implementing multimodal pain treatment strategies that combine pharmaceutical and nonpharmacological approaches.

Furthermore, Europe's dedication to healthcare innovation, which includes the development of innovative drug delivery methods and non-opioid drugs, helps to drive market growth for postoperative pain treatments by providing effective and patient-friendly alternatives.

Postoperative Pain Therapeutics Market: Segmentation Analysis

The Global Postoperative Pain Therapeutics Market is segmented based on Drug Class, Route Of Administration, Distribution Channel, And Geography.

Postoperative Pain Therapeutics Market, By Drug Class

  • Opioids
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Local Anesthetics
  • Tricyclic Antidepressants
  • Antiepileptic Drugs
  • Others

Based on Drug Class, the market is segmented into Opioids, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Local Anesthetics, Tricyclic Antidepressants, Antiepileptic Drugs, and Others. The opioids segment is estimated to dominate the Postoperative Pain Therapeutics Market due to their effectiveness in managing moderate to severe pain. Despite increasing concerns about addiction and the search for non-opioid alternatives, opioids remain popular in the postoperative setting due to their superior efficacy in treating acute pain. Opioids are used by healthcare practitioners for acute pain treatment after surgery, especially when the intensity of the pain exceeds the analgesic capacity of NSAIDs or local anesthetics.

Postoperative Pain Therapeutics Market, By Route Of Administration

  • Oral
  • Intramuscular
  • Intravenous
  • Others

Based on the Route Of Administration, the market is segmented into Oral, Intramuscular, Intravenous, and Others. The intravenous segment is estimated to dominate the Postoperative Pain Therapeutics Market during the forecast period. The intravenous route is preferable in hospitals due to its rapid start of action, accurate dosage control, and capacity to offer continuous pain relief, all of which are critical for managing acute postoperative pain. Furthermore, intravenous delivery is extremely beneficial for individuals who are unable to take oral drugs due to postoperative restrictions or nausea. The efficiency, control, and quick comfort given by the intravenous injection make it an essential component of postoperative therapy, assuring its market domination.

Postoperative Pain Therapeutics Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Based on the Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. The hospital pharmacies segment is estimated to dominate the market over the forecast period. This dominance is due to hospital pharmacies' direct involvement in the patient care process, particularly during the early postoperative period. Hospital pharmacies play an important role in the healthcare delivery system, ensuring that critical pain management drugs are available quickly after surgical procedures. This segment's popularity is bolstered by the high volume of surgeries conducted in hospitals, where thorough pain management protocols are vital to patient care, making hospital pharmacies an important component of the Postoperative Pain Therapeutics Market.

Key Players

  • The " Global Postoperative Pain Therapeutics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • AbbVie, Johnson & Johnson, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Eli Lilly and Company, GlaxoSmithKline plc, Baxter International Inc., Zimmer Biomet Holdings Inc., Boston Scientific Corporation, Medtronic plc, Stryker Corporation, Becton, Dickinson and Company, Smith & Nephew plc, and Altaris Therapeutics Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In February 2024, Pacira BioSciences announced positive findings from a Phase 3 trial of its long-acting local anaesthetic EXPAREL(R) in patients having bunionectomy surgery. The trial attained its primary goal of showing a statistically significant reduction in pain levels when compared to placebo.
  • In January 2024, Collegium Pharmaceutical introduced its new Xtampza ER(R) (oxycodone hydrochloride) extended-release tablets in a new 20mg dosing strength. This broadens the product portfolio for treating moderate-to-severe chronic pain.
  • In January 2024, Grunenthal demonstrated positive results from a Phase 2 research of its new nerve growth factor (NGF) inhibitor, Qsymia(R) (resiniferatoxin), for the treatment of post-surgical neuropathic pain. The findings revealed significant increases in pain levels and quality of life when compared to placebo.
  • In January 2024, Aprecia Pharmaceuticals expanded its Sprintec(R) (Aprecia Melt) line of fast-dissolving sublingual films with the introduction of Aprecia Melt Zuplenz(R) (ondansetron) for the prevention and management of nausea and vomiting associated with surgery.
  • In January 2024, Xeris Pharmaceuticals published findings from a Phase 2 study of GLYENA(R), a novel sustained-release local anaesthetic, for the treatment of postherpetic neuralgia. The findings revealed significant increases in pain levels and quality of life when compared to placebo.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET, BY DRUG CLASS

  • 5.1 Overview
  • 5.2 Opioids
  • 5.3 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • 5.4 Local Anesthetics
  • 5.5 Tricyclic Antidepressants
  • 5.6 Antiepileptic Drugs
  • 5.7 Others

6 GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1 Overview
  • 6.2 Oral
  • 6.3 Intramuscular
  • 6.4 Intravenous
  • 6.5 Others

7 GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 7.1 Overview
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies
  • 7.5 Others

8 GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL POSTOPERATIVE PAIN THERAPEUTICS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 AbbVie
    • 10.1.1 Company Overview
    • 10.1.2 Company Insights
    • 10.1.3 Business Breakdown
    • 10.1.4 Product Benchmarking
    • 10.1.5 Key Developments
    • 10.1.6 Winning Imperatives
    • 10.1.7 Current Focus & Strategies
    • 10.1.8 Threat from Competition
    • 10.1.9 SWOT Analysis
  • 10.2 Johnson & Johnson
    • 10.2.1 Company Overview
    • 10.2.2 Company Insights
    • 10.2.3 Business Breakdown
    • 10.2.4 Product Benchmarking
    • 10.2.5 Key Developments
    • 10.2.6 Winning Imperatives
    • 10.2.7 Current Focus & Strategies
    • 10.2.8 Threat from Competition
    • 10.2.9 SWOT Analysis
  • 10.3 Pfizer Inc.
    • 10.3.1 Company Overview
    • 10.3.2 Company Insights
    • 10.3.3 Business Breakdown
    • 10.3.4 Product Benchmarking
    • 10.3.5 Key Developments
    • 10.3.6 Winning Imperatives
    • 10.3.7 Current Focus & Strategies
    • 10.3.8 Threat from Competition
    • 10.3.9 SWOT Analysis
  • 10.4 Teva Pharmaceutical Industries Ltd.
    • 10.4.1 Company Overview
    • 10.4.2 Company Insights
    • 10.4.3 Business Breakdown
    • 10.4.4 Product Benchmarking
    • 10.4.5 Key Developments
    • 10.4.6 Winning Imperatives
    • 10.4.7 Current Focus & Strategies
    • 10.4.8 Threat from Competition
    • 10.4.9 SWOT Analysis
  • 10.5 Novartis AG
    • 10.5.1 Company Overview
    • 10.5.2 Company Insights
    • 10.5.3 Business Breakdown
    • 10.5.4 Product Benchmarking
    • 10.5.5 Key Developments
    • 10.5.6 Winning Imperatives
    • 10.5.7 Current Focus & Strategies
    • 10.5.8 Threat from Competition
    • 10.5.9 SWOT Analysis
  • 10.6 Merck & Co. Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Company Insights
    • 10.6.3 Business Breakdown
    • 10.6.4 Product Benchmarking
    • 10.6.5 Key Developments
    • 10.6.6 Winning Imperatives
    • 10.6.7 Current Focus & Strategies
    • 10.6.8 Threat from Competition
    • 10.6.9 SWOT Analysis
  • 10.7 F. Hoffmann-La Roche Ltd.
    • 10.7.1 Company Overview
    • 10.7.2 Company Insights
    • 10.7.3 Business Breakdown
    • 10.7.4 Product Benchmarking
    • 10.7.5 Key Developments
    • 10.7.6 Winning Imperatives
    • 10.7.7 Current Focus & Strategies
    • 10.7.8 Threat from Competition
    • 10.7.9 SWOT Analysis
  • 10.8 AstraZeneca plc
    • 10.8.1 Company Overview
    • 10.8.2 Company Insights
    • 10.8.3 Business Breakdown
    • 10.8.4 Product Benchmarking
    • 10.8.5 Key Developments
    • 10.8.6 Winning Imperatives
    • 10.8.7 Current Focus & Strategies
    • 10.8.8 Threat from Competition
    • 10.8.9 SWOT Analysis
  • 10.9 Eli Lilly and Company
    • 10.9.1 Company Overview
    • 10.9.2 Company Insights
    • 10.9.3 Business Breakdown
    • 10.9.4 Product Benchmarking
    • 10.9.5 Key Developments
    • 10.9.6 Winning Imperatives
    • 10.9.7 Current Focus & Strategies
    • 10.9.8 Threat from Competition
    • 10.9.9 SWOT Analysis
  • 10.10 GlaxoSmithKline plc
    • 10.10.1 Company Overview
    • 10.10.2 Company Insights
    • 10.10.3 Business Breakdown
    • 10.10.4 Product Benchmarking
    • 10.10.5 Key Developments
    • 10.10.6 Winning Imperatives
    • 10.10.7 Current Focus & Strategies
    • 10.10.8 Threat from Competition
    • 10.10.9 SWOT Analysis

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research